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Evaluation of a pharmacist-led cardiovascular risk clinic for patients with diabetes 




Cardiovascular disease is strongly associated with diabetes and is a major cause for 
disability and mortality among diabetic patients. Hypertension is prominent in 
diabetic patients, especially type 2 diabetics and 50% are receiving suboptimal 
hypertension treatment. In NHS Lothian, reducing blood pressure for hypertensive 
diabetic patients presented a challenge. A potential solution was to utilise the clinical 
pharmacist to solve this problem and in 2003 a pharmacist-led cardiovascular risk 
reduction clinic was established for that purpose. Initial evaluation suggests a 
promising reduction in blood pressure, lipid levels and improved prescribing quality 
but a comparison with usual care has not been conducte  through a prospective 
randomised controlled trial. 
 
Aim  
The aim of this study was to evaluate the feasibility of outcome measures to inform a 
future prospective study to evaluate the pharmacist-led clinic and to measure the 
impact of the clinic on cardiovascular risk reduction and the outcome of this 
intervention in terms of reduction in blood pressure, number of patients reaching 
target blood pressure and hospital admissions after discharge.  
 
Method 
Patients attending the pharmacist-led clinic were labe led the intervention group. A 
list of patients discharged from the clinic before 2009 was supplied by the pharmacist.  
Patients attending the usual care were labelled the control group and were chosen 
from lists of patients who had hypertension (BP>130/80mmHg) and/or 
microalbuminurea (ACR >3.5 mmol/L).  
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A spreadsheet was designed to be populated with patients’ information such as 
baseline characteristic at first visit, co-morbidities, physiological parameters, drug 
history, drug therapy problems, guidelines adherence and hospital admission after 




Forty five patients were included in the interventio  group and 42 in the control 
group. There were significant differences in baseline characteristics in terms of age 
(p=0.0006), duration of diabetes (p=0.003), HbA1c (p=0.026) and number of 
comorbidities (p0.022). The results showed a greate significant reduction in systolic 
blood pressure (p=0.0088) and a significant number of patients reaching target blood 
pressure (p =0.0036) in the intervention group. Reduction in diastolic blood pressure, 
ACR and total cholesterol was insignificant.  
The study also showed a significant difference in the number of antihypertensives 
started or increased (p<0.001) and a significant difference in the number of 
medication related problems actioned (p=0.0058). There were a greater number of 
hospital admissions among the intervention group. Reduction in systolic BP, 
reduction in diastolic BP and proportion of patients reaching target BP were used to 




Data collection proved challenging and barriers will have to be overcome in terms of 
access to follow up data in a prospective study. 
Reduction in blood pressure and the proportion of patients reaching target blood 
pressure change in pharmaceutical care plan drug therapy problems actioned can be 
used as an outcome measure and primary end point in the future study.  
Reduction in ACR and the number of hospital admission might be used as a feasible 
outcome measure if the intervention and the control gr up in the future study are 





ACE  - Angiotensin converting enzyme 
ACR   - Albumincreatinine ratio 
AMP-kinase -  Adenosine monophosphate kinase 
ARB  - Angiotensin-II receptor blocker 
BMI   - Body mass index 
BNF  - British National Formulary  
BP  - Blood Pressure 
CBVD  - Cerebrovascular disease 
CCBs   - Calcium channel blockers  
COPD  - Chronic obstructive pulmonary disease 
CVD   - Cardiovascular disease  
DBP   - Diastolic blood pressure  
DCVR  - diabetes cardiovascular risk  
DM   -  Diabetes mellitus 
DRP  -  drug related problems  
GDM  -  Gestational diabetes mellitus 
GP  - General Practitioner  
HbA1c  - Glycated hemoglobin  
HDL   - High-density lipoprotein  
HOT   - Hypertension Optimal Treatment  
IT   - information technology  
LDL   - Low-density lipoprotein  
MRP  - Medication related problems  
NHS  - National Health Service 
PVD   - Peripheral vascular disease  
RCT  - randomised controlled trials  
SBP  - Systolic blood pressure 
SCI-DC  - Scottish Care Information - Diabetes Collaboration 
SIGN  - Scottish Intercollegiate Guidelines Network  
UK  - United Kingdom 
WHO  - World Health Organisation  
WGH  - Western General Hospital  
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1. Introduction  
 
 
1.1 Pharmaceutical care 
 
In 1990 Hepler and Strand defined pharmaceutical care as “the responsible provision 
of drug therapy for the purpose of achieving definite outcomes that improve a 
patient’s quality of life. These outcomes are (1) cure of disease, 2) elimination or 
reduction of a patient’s symptomatology, (3) arresting or slowing of a disease process, 
or (4) preventing a disease or symptomatology”1 
 
Pharmaceutical care is not a term used to describe the profession of pharmacy, but 
rather a process of collaboration between different h althcare givers and the patient. 
The main objective of this process is to ensure dirct benefit of the patient. A 
pharmaceutical care plan identifies the patient’s medical conditions and patient’s 
drug-related needs, detects problems with drug therapy, develops an action plan and 
monitors to ensure the safety and effectiveness of the plan 2.  
 
Throughout the last century the profession of pharmacy has gone through 
fundamental changes. The big pharmaceutical companies took over medication 
production and ensured faster and more efficient distribution of medications to the 
population, the profession of pharmacy channelled into new fields, the bases of the 
profession became more patient centred rather than medicine centred.  
 
When drugs are given to patients there is always a possibility of undesired outcomes 
due to drug-related problems. There are several causes that could lead to drug-related 
problems, these causes can be categorised into five criteria:  suboptimal prescribing, 
suboptimal delivery of medicines, patients compliance, patients views on medications 
and suboptimal monitoring 1. Drug related problems are a burden for treatment and a 
costly social problem  
 
Due to their education and training, pharmacists play a vital role in pharmaceutical 
care. The cost of drug-related morbidity and mortality causes a substantial strain to 
the health system. It also forces new demands to improve pharmaceutical care and 
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improve health services offered to patients. All these factors gave the profession of 
pharmacy a leading role in pharmaceutical care, taking into account that these 
problems could be avoided using pharmaceutical knowledge.  
 
1.2 Chronic diseases worldwide 
 
The prevalence of chronic diseases is increasing and is a leading cause of death 
worldwide. The diseases affect all socioeconomical classes, but are mainly afflicting 
low and middle income class.  Chronic diseases account f r 63% of the mortalities 
worldwide, low to middle income countries account for 80-90% of cardiovascular, 
diabetes and chronic obstructive pulmonary disease (COPD) deaths worldwide. 
According to the World Health Organisation (WHO) the devastation afflicted by 
chronic diseases can be reduced drastically by reducing four main risk factors; 
smoking, physical inactivity, harmful alcohol consumption and unhealthy diet. 
Compliance was documented as an issue whereas only 50 % of patients comply with 
their medicines 3. 
 
The populations in low to middle income countries are subjected to uncontrollable 
marketing for tobacco, alcohol and junk food and most governments fail to regulate 
marketing leaving the population disposed to unhealt y marketing. The expenses of 
chronic disease treatment which is not covered by healt  plan is also a cause for the 
high mortality and morbidity, it forces patients to c ver all medical expenses which 
puts a strain on the patient’s budget.  
In order to improve the outcome of chronic diseases th  health systems worldwide 
must step in to monitor exposure, monitor morbidity and mortality of chronic disease 
and adapt plans and health policies to deal with the magnitude of chronic diseases 3. 
 
 
1.3 Patient’s journey in the UK vs. patient’s journey in 
Norway: 
 
In the United Kingdom (UK); the diagnosis of diabetes ake place mainly at General 
Practitioner’s (GP) clinics in primary healthcare; the patient’s medical needs and 
health are assessed by the doctor responsible for the patient. Patients can be referred 
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to the hospital to be treated at the diabetes clinics. Educational programs held by 
nurses are offered to the patients to improve their understanding of the disease. The 
role of the nurses extends beyond educational and motivational; they also play a role 
in monitoring and treating patients.  
In order to improve health services and improve patients’ access to medications the 
Scottish government granted nurses, pharmacists and other allied health professionals 
the right to prescribe medicines (non-medical prescribing) following accredited 
education and training 4.  
The diabetes patients can be referred to an ophthalmologist, a podiatrist, an 
endocrinologist or a nephrologist to prevent or to treat diabetes complications. 
Patients can also be referred to cardiovascular risk reduction clinics led by 
pharmacists to prevent and treat cardiovascular diseases associated with diabetes. 
These clinics offer optimisation of medical regimen, intensive care and monitoring, 
and frequent follow up for the patients.  
 
In Norway the diagnosis of diabetes take place at primary care; GPs or primary health 
clinics. The patients can attend educational programs introduced by diabetes nurses. 
Patients can also be referred to a dietician and physiotherapists to improve diet and to 
devise a plan for exercise. The monitoring and the assessment of patients are usually 
undertaken by the doctor.  If the patients require sp cial needs or the disease 
exacerbates they can be referred to the secondary he lthcare where specialists in 
endocrinology, cardiology and nephropathy assess and determine the appropriate 
treatment regimen for the patients.  
 
The diabetes services in Norway are not as diversifi d as in Scotland; there is no 
legislation to support non-medical prescribing. Nurses-led clinic and pharmacists-led 
clinics do not exist in Norway. Still, the clinical pharmacists are a part of a 
collaborative team to offer a complex intervention. They are utilised to optimise 






1.4 Diabetes mellitus 
 
Diabetes mellitus (DM) is a chronic endocrine disorder affecting the metabolism of 
carbohydrates, proteins and lipids. It is characterised by impairment in production of 
insulin with or without insulin resistance. Insulin is a hormone produced by β-cells in 
the pancreas, it plays a major role in metabolism of carbohydrates, proteins and lipids, 
as it facilitates uptake and storage of these components into the cells 5. Lack of insulin 
or resistance to it leads to hyperglycaemia (increased sugar levels in blood), which 
constitutes the major finding in diagnosis of DM. There are three types of DM: type 1 
DM, type 2 DM and gestational DM (GDM). GDM is characterised by insulin 
resistance during pregnancy 6.  
 
1.5 Type 1 diabetes mellitus 
 
 Type 1 DM accounts for 5-10 % of patients with diabetes and it may present at any 
age, but the majority of the patients will experienc  it at puberty 6. This disorder rises 
from destruction of β -cells in the pancreas which in 90% of the cases i due to 
autoimmune disease involving T-cell mediated destruction, the destruction of β-cells 
leads to reduced production of insulin. The rate of β-cell destruction varies in 
individuals being fast with some and slow with others. In addition some patients with 
diabetes will present with ketoacidosis as first sign of the disorder 6. Ketoacidosis is 
an acute emergency: fat, in anaerobic metabolism, i broken down to β -
hydroxybuterate (which causes the acidosis) and acetone, which is a ketone 7. 
 
1.6 Type 2 diabetes mellitus 
 
Type 2 DM is the most common type of diabetes, it accounts for 90-95 % of all 
diabetic patients. The disorder is more common among adults and the incidence of the 
disease rises with increasing obesity 6. The aetiology of this disorder is not fully 
understood and unlike Type 1 DM, β-cells destruction is not involved. The onset 
symptoms are much slower than that of DM type 1. Itis characterised by insulin 





1.7 Epidemiology of diabetes mellitus 
 
The percentage prevalence of DM is 8.3% worldwide and the number of diabetic 
patients worldwide is estimated to be 366 million in the year 2011. The number is 
estimated to increase to 552 million by the year 2030 with global prevalence of 9.9% 
8. Eighty percent of these diabetic patients live in developing countries and 183 
million people with diabetes are undiagnosed 8.  The rate of mortality due to DM 
worldwide is estimated at 4.6 million deaths in 2011 and the disease cost at least 465 
billion dollars in health expenditure in the year 2011 and the rate of diabetes 
morbidity and mortality keeps increasing every year 8.  
 
In Scotland the number of patients diagnosed with diabetes is estimated to be more 
than 228,000 which is 1 in 25 of the Scottish population, and there are at least 2000 
patients who are undiagnosed 9. It is estimated that 27000 people in Scotland have 
type 1 DM which accounts for 13% of all diabetic patients. More than 80% of diabetic 
patients have type 2 DM and the number of people with type 2 DM in Scotland is 
currently increasing at a rate of 4% per year. Diabetes requires a great deal of care and 
long term management due to multiple complications, the diabetes is thought to 
account for 10% of the total Nation Health Service (NHS) Scotland expenditure 9. 
 
According to the Lothian diabetes register of 2010, the number of diabetes patients in 
NHS Lothian is more than 32,000 people constituting more than 4% of the NHS 
population and  86.7 % of diabetes patients have type 2 diabetes10.  
 
 
1.8 The cost of diabetes 
 
DM accounts for 10% of the NHS UK budget which is estimated to be 9 billion 
pounds based on 2007/2008 NHS budget. In the UK, it is estimated that 1 in every 10 
hospital admissions is caused by DM or long term coplications related to DM. 
According to Diabetes UK in the year 2008, 28.4 million medications for DM 
treatment were prescribed at a cost of £ 561.4 million and diabetes prescribing now 
accounts for 7 % of all prescription costs 11. Due to complications and prolonged 
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monitoring requirements diabetes patients occupy aproximately 80,000 bed days per 
year in the UK 11. In addition the presence of diabetes complications ncreases the 
cost of social services by four fold. In Scotland, diabetes accounts for 5% of the NHS 
expenditure. In 2002/2003 the diabetes cost was estimated to be 32 million pounds 12. 
 
 
1.9 Diabetes complications 
 
There are multiple complications associated with diabetes; the complications can be 
divided into acute and chronic. The acute complications are polyuria, polydipsia, 
weight loss and ketoacidosis which can be life threatening 6. The long term 
complications arise from poor diabetic control and presence of risk factors. Risk 
factors include obesity, unhealthy lifestyle, physical inactivity, smoking and heavy 
alcohol consumption. The complications can be divided into macrovascular (damage 
to the large blood vessels) and microvascular (damage to the small blood vessels) 13. 
 
 
1.10 Macrovascular disease 
 
There is a significant increase in macrovascular complications in patients with 
diabetes. Macrovascular complications are cardiovascul r disease (CVD), peripheral 
vascular disease (PVD) and cerebrovascular disease (CBVD). Cardiovascular disease 
is the most common cause of death for diabetes patients. Factors that will increase the 
probability of CVD are smoking, dyslipidemia, hypertension and nephropathy. The 
incidence of CVD is greater in patients with diabetes than in those without diabetes. 
CVD is responsible for increased mortality rate andreduced life expectancy in this 
patient group. The reduction of CVD risk can be achieved by intensive glycaemic 
control, reduction in blood pressure (BP) to a target level and reduction of 
dyslipidemia to a target level 13.  
 
 PVD affects blood vessels outside the heart, mainly the legs and the feet; PVD is 
associated with atherosclerosis and thrombosis leading to neuropathic pain in the legs 
and loss of feeling in the feet. Approximately 20% of diabetes patients with PVD die 
of myocardial infarctions within two years of symptom onset. Cerebrovascular 
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disease is caused by atherosclerosis. Atherosclerosis followed by plaque formation 
leads to occlusion and reduction in blood flow and thrombosis which also leads to 
stenosis of the intracerebral arteries. The BP fluctuation and the embolism can cause 
ischemic stroke damaging the blood vessels and causing intracranial haemorrhage 14.  
 
 
1.11 Management of diabetes  
 
Diabetes management is a complex intervention. This intervention aims to offer 
medical and non-medical therapy options for the patient. Non-medical therapy 
includes lifestyle advice on diet, exercise, smoking cessation and reducing alcohol 
consumption 13. 
 
1.12 Lifestyle factors 
 
Patients with DM are offered lifestyle changing advice to help them in controlling the 
disorder. This support can be in the form of education programmes or consultations 
with dieticians to promote healthy lifestyle and discourage unhealthy habits. Patients 
who have poor diet and are obese should be encouraged to reduce fat, sugar and 
carbohydrate intake in order to achieve healthy weight and normal body mass index 
(BMI) 13. Physical activity should be encouraged regardless of BMI status. Exercise 
and physical activity can help prevent CVD and reduces hyperglycaemia and 
dyslipidemia. Unhealthy habits that affect quality of life should be discouraged. 
Smoking is hazardous to health and is a major contributor to CVD; in addition it is a 
major factor preventing physical activity. All smokers should be advised to cease 
smoking 13.  Patients who consume alcohol should be advised to reduce alcohol 
consumption. The alcohol limit for men is no more than 4 units in any one day and for 
women is no more than 3 units of alcohol in any oneday.  
 
1.13 Medical management of Hyperglycaemia 
 
Intensive glycaemic control is associated with reduction in microvascular and 
macrovascular complications associated with DM. Macrovascular disease risk 
increases when Glycated hemoglobin (HbA1c) exceeds 8% which is the upper normal 
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reference value. Hyperglycaemia can be diagnosed by directly measuring blood sugar 
levels or by measuring HbA1c which indicates the blood sugar levels for the last 8-12 
weeks. A 1% increase in HbA1c leads to 11% increased ri k for CVD 13.  
Oral anti-diabetic drugs and insulin preparation are used to control hyperglycaemia. 
Patients with type 1 diabetes can only be managed with insulin preparations whereas 
patients with type 2 diabetes can be prescribed either oral anti-diabetic and/or insulin 
preparations. The two main classes of oral anti-diabet c drugs are biguanides and 
sulfonylureas. 
 
Biguanides (eg Metformin) activate the enzyme Adenosi e monophosphate kinase 
(AMP-kinase) in the liver which leads to reduced hepatic output of glucose and 
improves peripheral glucose disposal. Metformin is considered the first line oral 
treatment for overweight patients with type 2 DM because it suppresses the appetite 
and promotes weight loss 13.  
 
Sulphonylureas (eg Gliclazide) increase endogenous release of insulin from 
pancreatic β-cells and increase tissue sensitivity to improve the action of insulin. 
Sulphonylureas may also promote increased systematic bioavailability of insulin due 
to reduced hepatic extraction of insulin secreted from the pancreas. Side effects 
include weight gain and higher probability of hypoglycaemia compared to metformin. 
Sulphonylureas should be considered as first line treatment for non obese patients or 
patients who do not tolerate metformin 13.  
 
There are other types of oral anti-diabetic drugs that are used less frequently, these 
can be used in combination with metformin or sulphonylureas or could be used alone. 
The mechanism of action varies, some amplify insuli secretion (eg saxagliptin), 
others enhance the action of insulin (eg pioglitazone) and some inhibit carbohydrate 
digestion (eg acarbose) 13, 15.  
 
1.14 Hypertension and cardiovascular risk reduction  
 
Hypertension is strongly associated with diabetes, mainly with type 2 DM; it is also 
an independent risk factor for macrovascular and microvascular complications 
associated with diabetes. Studies have shown the risks of hypertension: a 5 mmHg 
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increased in diastolic blood pressure (DBP) can lead to 20-30% increase in 
cardiovascular disease 16.  The threshold for hypertension differs between the diabetic 
population and the rest of the population, due to the risk of cardiovascular disease 
associated with diabetes. The threshold for non-diabet c patients is 140/90mmHg 
while for diabetic patients it is 130/80mmHg.  
 
In a Hypertension Optimal Treatment (HOT) randomised trial: 1501 patients with DM 
were randomised into three groups: BP≤ 90 mmHg, BP≤ 85 mmHg, BP≤ 80 mmHg. 
Cardiovascular events in the BP≤ 80 mmHg group were halved compared to the 
BP≤ 90 mmHg group. It also demonstrated a reduction in myocardial infarction, 
stroke and cardiovascular mortality. The results presented by the HOT study became 
adapted as a general definition for hypertension in diabetes treatment guidelines 17. 
The systolic threshold of 130 mmHg is a locally approved limit for systolic blood 
pressure (SBP). 
Hypertension can present itself at different stages of the disease. For type 1 diabetics 
hypertension is present in approximately 30% of the patients and takes time to ensue 
up to several years after the diagnosis. Hypertension in type 2 diabetics can be 
presented before the development of the disease due to patients being older and 
generally overweight 16.  
 
Hypertension should be treated aggressively with lifestyle modifications and medical 
treatment. Drugs incorporated into treatment guidelines are usually selected according 
to BP reduction properties, cardiovascular risk reduction properties, nephropathy 
reduction and renal function improvement properties and adverse drug reactions.  
Diuretics have demonstrated a BP lowering property, mainly by elimination of 
sodium from the body. Until recently, a thiazide diuretic was first line. Beside the 
diuretic effect it has shown a vasodilatory effect. The main adverse drug reaction is 
hypokalemia and as renal function worsens, thiazides become ineffective as it is 
associated with lose of renal function. Loop diuretic (Furosemide) is a subclass of 
diuretics, just like thiazide, it also has a vasodilatory effect. It can be used instead of 
thiazide if the renal function deteriorates 16. 
The Renin-Angiotensin-Aldosterone Axis is a system in the body involving many 
organs utilized to balance electrolyte levels and fluids in the body, making it a vital 
target for antihypertensive medications. Angiotensin-converting enzyme (ACE) 
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inhibitors can be used as first line treatment for hypertension in diabetic patients. 
ACE-inhibitors lower BP and slow the progression of renal disease by reducing the 
rate of progressive loss of glomerular filtration rate independent of level BP  
reduction18. ACE-inhibitors are effective in preventing nephropathy and retinopathy 
16. ACE-inhibitors inhibit bradykinin degradation whic  can cause dry cough forcing 
patients to switch to Angiotensin receptor Blockers (ARB). ARBs induce blood 
pressure reduction through the same system as ACE-inhibitors and possess the same 
renal protective action as ACE-inhibitors, but do not i hibit Bradykinin.  
 
High levels of circulating aldosterone lead to increased BP through fluid retention and 
increased albuminuria. Aldosterone blockers (Spironolactone) have demonstrated 
effectiveness in BP reduction when used in combinatio  with ACE-inhibitors and 
reduction in albuminuria 19. Because of severe hyperkalemia, aldosterone blockers 
cannot be used as monotherapy and are not first line reatment agents.  
 
Calcium channel blockers (CCBs) bind to calcium channels located on the membrane 
and block the influx of calcium leading to vasodilatation. CCBs are effective in 
reducing BP and are used in combination with ACE-inhibitors or ARBs 18. Oedema is 
a common side effect of the CCBs especially in the ankles.  
 
β-Blockers are the least effective anti-hypertensive ag nts and less effective at 
preventing stroke than other agents 18. β-Blockers are not suitable for initial 
hypertension treatment due to observed increase in cardiovascular mortality 13. 
  
α-blockers are not suitable for initial hypertension treatment due to observed increase 
in heart-failure. They are used for patients who cannot reduce their BP with first line 
treatment.  
 
1.15 Dyslipidemia and cardiovascular risk reduction 
 
Dyslipidemia has a strong association with type 2 diabetes. Many patients are 
characterized with obesity, low High-density lipoprtein (HDL), high Low-density 
lipoprotein (LDL), high cholesterol and triglycerides. Dyslipidemia is considered as a 
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risk factor because of the presence of small dense LDL-particles and oxidation of 
glycated LDL-particles 5. These abnormalities accelerate the atherogenesis 
progression, damaging the heart muscle and blood vessels.  Statin treatment for 
lowering lipid levels is recommended as first line pr vention of CVD for type 1 and 
type 2 diabetic patients whom are older than 40 years regardless of the cholesterol 
baseline. Statin therapy (whether Simvastatin 40mg or Atorvastatin 10 mg) is shown 
to reduce cardiovascular events comprising stroke, acute coronary events and 
coronary revascularisations 13. This reduction of cardiovascular events arises from the 
different action modes of statins as they, improve endothelial function, reduce 
vascular inflammation,  reduce platelet aggregability, increase neovascularisation of 
ischemic tissue, increase circulating endothelial progenitor cells, stabilisations of 
atherosclerotic plaque and antithrombotic  actions 5.  
 
 
1.16 Pharmacist-led diabetes cardiovascular risk clnic 
 
In NHS Lothian, despite the development of prescribing guidelines and patients’ 
attendance at hospital specialist out-patient clinics, achieving target BP continued to 
be a challenge. The pharmacists’ role in pharmaceutical care was considered a 
potential solution to this challenge and a pharmacist-led diabetes cardiovascular risk 
(DCVR) clinic was established in 2003 within primary nd secondary care sites in 
NHS Lothian. The clinics were established using short-term funding and aimed to 
monitor, treat and reduce the risk factors that lead to CVD in diabetic patients. The 
clinic has shown promising results in reducing BP, lipid levels and HbA1c and 
established funding continued to allow three clinics in NHS Lothian at three different 
sites. Limited funding limits the number of pharmacists working in the clinics, 
limiting the number of patients seen by the clinics and the time dedicated for every 
appointment. Some of these clinics operate once a wek others are limited to once a 
month. 
 
The referral criteria to the clinic are broad and may not guide physicians who are less 
familiar with the clinic than those involved in itse tablishment. Referred patients tend 
to be hyperglycaemic, hypertensive and dyslipidemic. These patients are considered 
resistant to treatment and are at high risk of developing cardiovascular complications. 
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In the initial consultation, BP measurements are tak n, the medical history of the 
patient and medication list is confirmed. There are approximately 60 patients referred 
to the pharmacist-led clinic per annum. 
The pharmacists in the clinic have access to the electronic patient record database 
SCI-DC (Scottish Care Information - Diabetes Collaboration) to obtain medical 
record, patient’s history and blood and urine analysis results of the diabetic patient 20.  
The SCI-DC project started in 2002 to improve diabetes services in NHSScotland. 
The aim of the project was to introduce an information echnology (IT) system for 
diabetes care, an electronic patient record database and all involved in diabetes care 
are granted an access to the program. The patient’s medication adherence is also 
assessed. Blood and urine samples are collected in or er to work up a pharmaceutical 
care plan 21. The pharmacist in collaboration with the diabetes physicians has 
developed guidelines for reduction of cardiovascular disease risk. The first guideline 
was used in 2003 until 2005, second guideline used between 2005 and 2010 and the 
latest guideline was developed in 2010 and is still being used (see appendix 1). The 
pharmacist in cooperation with the diabetic consultant recommends changes to the 
prescribed medicine regimen, either by increasing a dosage, commencing a new 
medication or stopping medication the patient is currently using. These 
recommendations are usually sent to the GP responsible for the patient to commence 
in primary care. The pharmacist sends the letter using the same process as letters 
would be sent from the specialist physician. In NHS Scotland no prescribing takes 
place in the out-patient clinic, recommendations are made to the GP for continued 
prescribing for chronic diseases. 
 
Due to limited number of staff,  limited time for each consultation and the great 
number of diabetic patients, the patients are followed up approximately once every six 
weeks until target BP is achieved or no further improvement can be obtained 21.  
 
Usual care – patients who are not referred to the pharmacist-led clinic are seen by the 
physician in the diabetes unit. The main focus of the physicians is to initiate and 
optimise diabetes treatment. However they can make changes to the antihypertensive 
and cardiovascular treatment. The usual care can offer appointments to more than 
3000 patients per annum, but not as frequent as the pharmacist-led DCVR clinic. 
Depending on diabetes control, usual care can offertwo to three appointments per 
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annum for patients with poorly controlled diabetes. If diabetes is under control 
patients are offered a single appointment every year, patients are seldom discharged, 
unless request to be discharged, they still receive appointments. The treatment 
protocol used in the usual care is vague and not as well defined as the treatment 
protocol used by the pharmacist-led DCVR clinic (trea ment guideline for diabetes 
clinic included in appendix 2).  
 
1.17 Previous work to evaluate the pharmacist- led DCVR 
clinic 
 
A small audit, in which 10 patients were interviewed to explore their views on the 
clinic showed that most patients reported being satisfied with the service provided and 
can report better understanding of hypertension and antihypertensive treatment also 
that most patients increased their understanding of better healthy lifestyle, but only 
few committed to change their lifestyle 22.  
In a study of 40 patients assessing the cardiovascul r risk reduction showed a 
decrease in clinical BP upon clinic entry, discharge and follow up.  The study also 
showed a decrease in lipid values, change in the total number of antihypertensive 
medications and dose increase of antihypertensive, also a change in type of statin or 
dose increase 21. In order to eliminate bias and other variables that could affect the BP 
monitoring the patients were given a 24-hour ambulatory BP monitoring device. A 
significant decrease with an average of 13/9 mmHg was recorded from clinical entry 
to 6 months after discharge 21 . A significant change in cholesterol levels was 
observed, reduction from 4.46 ± 0.90 mmol/ L on referral to 4.02 ± 0.72 mmol on 
discharge (p=0.002) 21. 
 
Both studies suggest benefits of the clinic in improving medication regimens of the 
patients. These finding can be interpreted in terms of impact of reducing risk of CVD 
and the subsequent cost reduction of treating the CVD complications. However, there 
is a need to conduct rigorous evaluation of the clinic and compare outcomes to those 
achieved in patients who attend the clinic without referral to the pharmacist. No 
randomised controlled trials (RCT) have been conducted to demonstrate effectiveness 
of this complex intervention. 
 22 
 
1.18 MRC framework and complex interventions 
 
 
A complex intervention is a recognised term that can be applied to the health care 
offered by different healthcare practitioners who collaborate with each other. “It 
comprises a number of separate elements which seem essential to the proper 
functioning of the interventions although the 'active ngredient' of the intervention that 
is effective is difficult to specify. Complex interventions are built up from a number 
of components, which may act both independently and interdependently. The 
components usually include behaviours, parameters of behaviours (e.g. frequency, 
timing), and methods of organizing and delivering those behaviours (e.g. type(s) of 
practitioner, setting and location)”23 
 
The pharmacist-led DCVR clinic can be considered as a complex intervention. If it 
was to be evaluated both the process in the clinic a d the process experienced in the 
usual care would need to be defined to inform outcome measures and processes which 
could be applied in a prospective RCT. Before designing a full scale evaluation, a 
feasibility study needs to be conducted. This is required to define process and 
outcome measures for a definitive future RCT. The feasibility study will identify 
problems with recruitment, potential sample size and estimated difference in outcome 
measures. Feasibility studies help to overcome uncertainties associated with the 
method used in the full scale evaluation and makes th  evaluation more reliable 24.  
 
The full scale evaluation of the clinic not only can be used to measure outcomes of the 
clinic, but also can be used to fine tune an improved model of delivery of the complex 
intervention offered by the clinic. It also can lead to change in the organizational 
structure of the health care offered to diabetic patients 25.  
 
1.19 Outcome measures 
 
In order to evaluate the clinic, relevant and feasible outcome measures must be 
decided upon. A feasibility study was designed to re rospectively review data 
available for the pharmacist-led DCVR clinic and the usual clinic using data collected 
from the SCI-DC program and the notes written by the p armacist upon the 
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consultations. The retrospective nature will not include patient interviews. Data 
collection will include the change in status of hypertension, dyslipidemia and blood 
sugar levels and changes in lifestyle habits of the patient 26. Change in the 
pharmaceutical care plan will be assessed using the pharmacist notes and SCI-DC to 
find drug related problems and changes to patients’ treatment in the clinic, including 
changes to the number of medication or dosage/ form. Patient admission, re-
admission to the hospital and the length of hospitalisation will be recorded to assess if 
these are feasible outcome measures for a definitive trial. 27.  
 
1.20 Advantages and disadvantages of prospective vs. 
retrospective study design  
 
Prospective study usually take place over a long period of time, where the population 
included in the study is well defined and the population in general have a common 
characteristic. This kind of study design can be used to establish causality between the 
variables observed and the results obtained.  
 
To use prospective study design to evaluate the clinic, outcome measures must be 
assigned before undertaking the study. The inclusion criteria must be decided prior to 
study start and then the population is divided intoervention group (patients 
managed in the  pharmacist-led DCVR clinic) and a control group (patients managed 
in the  normal clinic) Pre-assigning inclusion crite ia and measurable outcomes can 
reduce sampling bias, design bias and selection bias 28.  
The time required to accomplish prospective study can be disadvantageous. In the 
feasibility study we decided to study data from patients who had attended the clinic 
for at least 12 months and then followed them up for three years after discharge from 
the clinic in order to compare hospitalisation rate with patients in the comparative 
arm. Comparison of outcomes will inform sample size calculations and period of 
follow up required for a definitive prospective trial. The sample size and duration of 
follow up will inform the design and the costing for a research grant proposal.  
 
Retrospective study design has limitations in terms of matching patients to inclusion 
criteria, potential for sampling bias, reliance on accurate documentation and 
completeness of data and the need to retrospectively ‘cl an’ data. This design can be 
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more economic as large numbers of patients’ records can be examined in a short 
period of time 28.  
 
We decided to use retrospective design in a feasibility study to assess if the data 
currently collected routinely in practice could be used for evaluation in a future study. 
As this data already existed it was also feasible in a short period of time, to examine 
data over a period of time estimated to provide measures of outcome and potential 





















2.1 To define outcome measures and the feasibility of data collection to inform a 
future RCT prospective study to evaluate the pharmacist-led DCVR clinic. 
2.2 To define the size of effect of the pharmacist-led DCVR on outcome measures 
such as proportion of patients reaching BP target, proportion of quality standards 
reached for prescribing and hospital admission after discharge from the clinic to 
inform future power calculations.  





3.1  To characterise the diabetic population managed in NHS Lothian to 
include those who attend the secondary care diabetes clinics and those who attend 
or are eligible to attend to the pharmacist-led DCVR clinic 
3.2  To compare outcome measures between patients eligible to attend the 
pharmacist-led DCVR clinic whom attend the secondary c e diabetes clinic and 
patients who attend the pharmacist-led DCVR clinic i  terms of admission rates 
after discharge from clinic, reasons for admission, le gth of hospitalisation, 
proportion meeting target BP, time to achieve target BP, lipid targets and drug 
related problems (DRP) to inform future evaluation.  To correlate with 
pharmaceutical care issues outcome measures between the two groups will be 
compared to explore the feasibility of future evaluation including economic 
evaluation. 
3.3  To compare time to dialysis, changes in albumin ria and BP in the 
subgroup of patients who attend the renal diabetic clinic between those who are 
referred to the pharmacist and those who are managed by usual care (secondary 
care diabetes clinic).  
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4. Subjects and settings 
 
4.1 Research approval 
 
The scientific officer of the South East Scotland Research Ethics services confirmed 
the study did not require research ethics approval (Appendix 3). The study was 
approved by the Pharmacy Quality Improvement Team. The investigator was an 
ERASMUS exchange student from the University of Tromsø whom had an honorary 




The study was undertaken at the Western General Hospital (WGH), Edinburgh. The 
design of the spreadsheet for data collection was performed at the Education, 
Research & Development department in collaboration with an administrator linked to 
the supervisory team.  
The process of data collection took place partially t the diabetes unit, but mostly at 
the medical record office.  
 
 
4.3 Subjects inclusion and exclusion  
 
Patients were recruited retrospectively from the WGH. Patients attended the 
pharmacist-led DCVR clinic represented the intervention group. Patients managed by 
the diabetes clinic represented the control group.  
 
The diabetes clinic offers approximately 3000 appointment per annum to diabetes 
patients. GP refer patients to the diabetes clinic to be managed by doctors to initiate or 
to optimise diabetes treatment and/or associated cardiov scular risk. Patients are 
offered up to three appointments every year depending on the rate of progression of 
DM and CVD. The doctor at the clinic recommends a tre tment plan and the GP 
follows this plan in primary care. Approximately 60patients are referred to the 
pharmacist-led DCVR per annum. The pharmacist focuses on management of 
cardiovascular risk factors. The clinic operates once a week and patients are offered a 
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review once every 6-8 weeks. Recommendations to change cardiovascular treatment 
are sent to the GP to commence changes in the primary care using the same process as 
letters from doctors.  
 
Using SCI-DC a list of all patients who attended the clinic in 2007 whom had either 
hypertension, microalbuminuria or both were identified. Patients who were eligible to 
attend the pharmacist-led DCVR clinic and were not referred were included.   
Deceased patients, non-attendees and patients who had relocated were excluded as 
data was not available. Patients were also excluded if they had clear reasons for 
unstable BP, for example those who were pregnant, breast feeding or who had white 
coat hypertension. Patients who were attending boththe pharmacist-led DCVR clinic 
and the usual clinic or renal clinic for management of cardiovascular risk factors were 
also excluded.   
 
The initial proposal to include patients who had attended the clinic for 12 months was 
changed to 4 months as patients were seen a number of times within this time-frame 
and some patients were discharged from the clinic within 12 months. To allow enough 
time for hospital admission/re-admission it was proposed to collect data for patients 
who had been discharged from the clinic before 2009 providing a follow up period of 
3 years. It was discovered that most patients attending usual care are not discharged 
despite being stable and at target physiological parameters; they continue to receive 
appointments varying between once or twice each year. Patients attending the 
pharmacist-led DCVR clinic are discharged after twoconsecutive visits with BP on 
target. Data from those in the usual care group was recorded up to three years from 
the first episode of cardiovascular risk. 
 
Recruitment was initially modified to ease evaluation of guideline adherence. 
Treatment protocols had been updated in 2005 and in 2010. Patients were therefore 
recruited from those who had been referred to the clinic after 2005 and discharged 
before 2009. Following exclusion of patients as described above, numbers of eligible 
patients were inadequate and it was decided to include patients referred to the clinic in 
2003-4 as differences in the treatment protocols 2003 and 2005 were minor. The time-
period was used to recruit eligible patients for the usual care group. SCI-DC database 
could not perform a search to identify usual patients that fit the time parameter for the 
 28 
inclusion criteria nor referral eligibility due to cardiovascular risk. Instead a list of all 
patients who attended the usual care in 2007 was generated (3300 patients), but was 
not purposeful; not all patients were eligible to be referred to the pharmacist-led 
DCVR clinic and the list did not include dates of re erral and discharge from the 
clinic. A list of patients using cardiovascular medications was generated from the 
2007 patients list, but the list did not include patients who had hypertension but were 
not treated. It was decided to generate three lists that included all the patients eligible 
to be referred to the pharmacist-led clinic; the first list included patients who had 
hypertension in 2007(BP>130/80mmHg), patients who had microalbuminuria in 
2007(Albumin/Creatinine Ratio (ACR) >3.5 mg/mmol) and patients who had both 
hypertension and microalbuminuria in 2007. Patients who had two or more 
consecutive episodes of hypertension and/or microalbuminurea were identified. 
Patients treated at the pharmacist-led DCVR clinic, deceased patients, patients 
relocated, transferred to another hospital and non-attendees were identified using SCI-
DC database and excluded. A list of patients who match the inclusion criteria was 
generated and randomised.  
In total 45 patients from the pharmacist-led DCVR clini  were included (intervention) 



















5.1.1 Patients who attended the pharmacist-led DCVR clinic were recruited 
retrospectively; a list of patients discharged from the clinic before 2009 was 
supplied by the pharmacist.  
 
5.2.2 It was anticipated that data could be retrieved from the SCI-DC database and 
the pharmacist’s records. Data was incomplete therefore it was decided to 
undertake case note review using paper medical records. The investigator was 
granted access to the WGH medical records office in order to collect medical 
data. The pharmacist’s notes were excluded as a source f data collection as 
the medical records contain more substantial information and are easier to 
interpret compared to the pharmacist’s notes.  
 
 
5.1.2 Data collection documents were allocated an identifica on number linked to a 
list of patient names and date of birth to make it possible to collect additional 
patient information if required at a later period.  The list of patient names was 
kept in a locked filing cabinet within the Education, Research and 
Development department within the pharmacy department at the WGH. No 
patient identifiers were required for analysis.  Anonymised data was 
transferred onto a password accessed Microsoft Access database. The database 
was designed to enable collecting data about demographics of patients (age, 
sex, duration and type of diabetes etc.), clinical parameters (BP, lipid values 
and kidney function status), drug history, medication related problems (MRP), 
guideline adherence and hospital admissions. The data base was tested by 
collecting information from 3 patients and was modifie  accordingly to enable 
gathering appropriate information and minimise time consumed to gather 
information.  
5.1.3 Using SCI-DC and the medical record, the general demographics of the 
population of patients who attend the secondary care linic who are eligible to 
attend the pharmacist-led DCVR clinic and the population of patients who 
attended the pharmacist-led DCVR clinic were recorded in a spread sheet 
developed by the investigator and the administrator linked to the supervisory 
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team. The demographics included: age, sex, type, duration and method of 
control of diabetes, co-morbidities, smoking habits, exercise habits and 
alcohol consumption on referral and when discharged. The demographics were 
compared between the two groups.  
 
5.2.1 A literature search was performed to determine the most common outcome 
measures investigated when evaluating similar complex interventions. 
MeSH term in search engine Pubmed was used to search for studies containing 
the following key terms: pharmacist clinic AND diabetes, pharmacist clinic 
AND cardiovascular disease, diabetes AND cardiovascul r disease, diabetes 
AND hospital admission, cardiovascular disease AND hospital admissions.  
Pubmed, Embase, Medline and Google were used to search for articles 
containing the following terms: diabetes outcomes, cardiovascular outcomes, 
diabetes hospitalisation and cardiovascular hospitalisa ion.  
5.2.3 The investigator and the supervisors agreed on three classes of outcome 
measures: changes in physiological parameters changes i  pharmaceutical care 
plan and impact of clinic on hospital readmissions. Changes in physiological 
parameters include change in BP between referral and discharge, change in 
lipid profile (total cholesterol, triglycerides, HDL-cholesterol) between 
referral and discharge and change in kidney functios (creatinine, ACR and 
urea) between referral and discharge. Change in pharmaceutical care plan was 
subcategorised into 8 classes of drug therapy problems using the definition 
established by Cipolle and Strand ; Unnecessary drug therapy, Additional drug 
therapy, Ineffective drug, Dosage too low, Adverse drug reaction, Dosage too 
high, Inappropriate compliance and Unclassified 2. Guideline adherence was 
compared between the two clinics. Any deviation from the guidelines and the 
reason for non-adherence was recorded.  Non-guideline adherence was 
subcategorised into four classes; choice, drug, unknown and non-applicable. 
Choice covers the deviation in dose, frequency and form of the medication. 
Drug covers the deviation in the type and class of medication. Unknown 
covers the deviation from guidelines without any justifiable reasons. Non-
applicable covers the deviations when guidelines cannot be applied to certain 
situations.   
 31 
Time to first hospital admission, number of subsequent admissions, length of 
hospitalisation and reason for admission are recorded and compared between 
the two clinics.  
Mean and SD will be calculated for the different parameters, if not appropriate 
percentages and proportions will be calculated instead.  
To demonstrate statistical difference, p value willbe calculated, depending on 
the type of data, z-test, t-test and χ2-test will be used accordingly to calculate 
the p-value.  
5.3.1 The investigator was not granted access to the medical files of the patients 
experiencing care at the renal clinic. The subgroup f atients who attended 
the renal clinic was excluded from the study. The renal clinic was established 
recently which does not fit the time parameter in the inclusion criteria for 




















6. Results  
 
6.1 Characterisation of diabetes population managed in NHS 
Lothian  
 
A total of 87 patients were included in the study, 45 patients experienced health care 
at the pharmacist-led DCVR clinic (intervention group) and 42 patients were treated 
in the usual care (control group).  
Most patients in both groups had type 2 DM. Patients i  the intervention group were 
significantly older than those in the control group and had a longer duration of 
diabetes. A greater proportion of patients in the int rvention group used insulin.  
The baseline physiological values were collected from the first appointment at the 
clinics. Baseline SBP, ACR and total cholesterol did not present significant difference 
between the groups (p=0.25, p=0.30, p=0.22). The bas line DBP and HbA1c 
presented a significant difference (p= 0.0003 and p=0.026). The intervention groups 
had a significantly greater number of cardiovascular medications on referral 
(p<0.001) and a greater mean of comorbidities per patient (p=0.022) Patient 
demographics are described in table 1.  
 
Table 1: General demographics of the intervention and the control group at baseline 
 
Characteristics   Intervention   control   p-value  
 
Number of patients  45   42     
Mean age (SD) years  64.58 (10.29)  56.69 (11.12)  0.0006 
          (z-test) 
Males    22 (48.89%)   24 (57.14 %)  
Weight (Kg)   93.33   88.05   0.26  
          (z-test) 
BMI    34.47   31.90   0.11 
          (z-test) 
Type 2 DM    44 (97.78%)  37 (88.10%) 
Type 1 DM     1 (2.22%)    5 (11.90%)  
Duration of disease  104.28   30.81   0.003 
(Months)         (z-test) 
 
Diabetes method of control     
 Diet    5 (11.11%)  4 (9.52%) 
 Tablets   24 (53.33%)  29 (69.05%) 
 Insulin only   9 (20.00%)  7 (16.67%) 
 Insulin & Tablets  7 (15.56%)  2 (4.76%)  
 
Smoking status  
 Smoker    10 (22.22%)  12 (28.57%) 
 Ex-smoker   7 (15.56%)   7 (16.67%) 
 Never smoked   26 (57.78%)  21 (50.00%)  
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Table 1 continued 
 
Characteristics    Intervention   control   p-value  
 
Unknown     2 (4.44%)  2 (4.76%)   
 
Alcohol consumption  
 Excess limit     4 (8.88%)    4 (9.52%) 
  Within limit   15 (33.33%)  11 (26.19%) 
 Non-drinker   11 (24.44%)    3 (7.14%)   
Unknown  15 (33.33%)   24 (57.14%) 
Activity status  
 Slight active   15 (33.33%)   3 (7.14%) 
 Inactive    16 (35.56%)    2 (4.76%) 
 Unknown  11 (24.44%)  36 (85.71%)  
   
Blood pressure 
 Mean SBP (SD) mmHg 155.09 (19.02)  150.85 (15.31)  0.25 
     (n= 45)   (n=41)   (z-test) 
Mean DBP (SD) mmHg 80.38 (10.31)  88.32 (10.01)  0.00 3 
   (n= 45)   (n=41)   (z-test) 
Total Cholesterol   4.57 (0.95)  4.88 (1.10)  0.22 
    (n=27)   (n=36)   (t-test) 
ACR (mg/mmol)   22.5 (47.80)  11.62 (14.35)  0.30 
    (n=22)   (n=29)   (t-test) 
 
HbA1c    7.92 (1.46)  9.03 (2.09)  0.026 
    (n=17)   (n=41)   (t-test)  
 
Mean number of cardiovascular  4.53 (1.69)  1.54 (1.64)  <0.0001 
Medications on referral          (z-test) 
  
Co-morbidities  
Hypertension  41 (91.11%)  40 (95.24%)  
PVD    4 (8.88%)    0 (0%)  
Angina     5 (11.11%)    1 (2.38%)   
 IHD     9 (20.00%)    1 (2.38%)   
 MI     2 (4.44%)    1 (2.38%)  
 CABG      2 (4.44%)    2 (4.76%) 
 Stroke/TIA    3 (6.67%)   1 (2.38%) 
 Hyperlipidemia   15 (33.33%)  20 (47.62%)   
 Heart failure    0 (0%)     1 (2.38%) 
 Microalbuminurea 17 (37.78%)  19 (45.24%)   
 Nephropathy   10 (22.22%)    4 (9.52%) 
 Retinopathy    7 (15.56%)   1 (2.38%) 
 Neuropathy    8 (17.78%)   1 (2.38%)  
 
Mean number comorbidities 2.74 (1.36)  2.19(0.83)  0.022 
per patient         (z-test) 
Total number of comorbidities  123   92    
 
SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; ACR, Albumincreatinine ratio; PVD, Peripheral Vascular disease; 





6.2 Comparison of outcome measures between the 
intervention group and the control group 
 
The BP target to evaluate the number of patients reaching BP target were taken from 
the treatment protocol used in the pharmacist-led DCVR clinic: 
• Type 1 and 2 diabetics with no microalbuminurea- target < 140/80 mmHg  
• Type 1 diabetics with nephropathy - target < 120/70 mmHg 
• Type 2 diabetics with microalbuminurea – target < 135 / 75 mmHg 
The reduction of SBP was significantly greater in the intervention group, 19.18mmHg 
(p=0.0088) and a greater proportion of patients reach d the target BP in the 
intervention group (57.78%) than in the control group (26.83%)  (p=0.0038). The 
difference in reduction of DBP, total cholesterol and ACR was not significant 
between the two groups. The change in physiological parameter is summarised in 
table 2. 
Table 2: change in Blood pressure, Albumincreatinine ratio and Total cholesterol  
 
Characteristics    Intervention   control    P-value 
 
Change in SBP (mmHg)  Mean -19.18   Mean -8.34  0.0088 
    SD  19.86   SD 18.56  (z-test) 
SE  2.96  SE  2.90    
 n  45  n  41 
Change in DBP (mmHg)   Mean -9.36  Mean -6.78  0.28 
    SD 9.7  SD 11.97  (z-test) 
    SE  1.45  SE 1.87   
    n  45  n 41 
 
Number of patient reaching  26 (57.78)  11 (26.83%)  0.0038 
target BP (%)         (χ2-test) 
 
Change in ACR    Mean - 2.89  Mean -5.47  0.68 
    SD 29.27  SD 14.13  (t-test) 
    SE 6.24  SE 2.62   
    n 22   29 
Change in Cholesterol   Mean  -0.14  Mean  -0.69  0.52 
    SD 0.76  SD 1.12  (t-test) 
    SE 0.15  SE 0.20   
    n 27  n 35 
Change in HbA1c  Mean -0.04  Mean -1.72  0.0013 
    SD 1.14  SD 2.33  (t-test)  
    SE 0.34  SE 0.36 
    n 17  n 41   
 
SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; ACR, Albumincreatinine ratio; SD, standard deviation; SE, 
standard error; n, sample size.  
 
The pharmacist made a significant number of changes to the pharmaceutical care 
plan. In total starting 46 new antihypertensive therapies and increasing the dose of 30 
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antihypertensive therapies to the maximum recommended dose. The usual care started 
27 antihypertensive therapies and increased the dos of 12 antihypertensive therapies 
to the maximum recommended dose. A summary of all subclasses of antihypertensive 
therapies, antiplatelet therapy and lipid lowering therapy initiated and doses increased 
is summarised in table 3. 
 
 
Table 3: Change in pharmaceutical plan   
 
Medication     intervention    control  
 
ACE-inhibitors  
 Started     5    16   
Dose increased    19    11 
Dose increased to ≥ 100%  8    6  
 of recommended dose 
 
ARB  
 Started     5    2  
 Dose increased    8    5 
 Dose increased to ≥ 100%   6    3   
of recommended dose 
 
Calcium channel blocker 
Started     8    3 
 Dose increased    12    1   
Dose increased to ≥ 100%  9    1  
of recommended dose 
 
Started Thiazide     4    3  
 
Frusemide   
Started     5    1 
 Dose increased    4    1  
Dose increased to ≥ 100%  4    1 
of recommended dose 
 
Started β-blocker    5    2  
 
α-blocker        
Started     9    0 
 Dose increased    15    0  
Dose increased to ≥ 100%  2    0 
of recommended dose 
 
Spironolactone 
Started     5    0 
 Dose increased    8    0 
Dose increased to ≥ 100%  2    0 
of recommended dose 
 
ACE-inhibitor started or increased  24    27  
ARB started or increased   13    7  
Calcium channel blocker started or   20    4 
increased       
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Table 3 continued   
 
Medication     intervention    control  
 
Thiazide started or increased  4    3  
Frusemide started or increased  9    2  
β-blocker started or increased  5    2  
α-blocker started or increased  24    0  
Spironolactone started or increased  13    0  
Total      112    45 (p<0.001) 
         (χ2-test)  
 
Total number of antihypertensive    
increased to ≥ 100% of    30    12 
recommended dose  
 
Started Aspirin     5    10  
Started Clopidogrel    10    0 
 
Statin Started     10    23 
Statin dose increased    9    4  
Statin dose increased to ≥ 100%  6    2  
of recommended dose 
.  
ACE-inhibitors, Angiotensin Converting Enzyme inhibitor; ARB, Angiotensin Receptor blocker 
 
The total number of MRP documented in the intervention group were twice as much 
the number of MRP documented in the control group (p=0.0058). The most 
prominent MRPs documented were the need to add a drug therapy (71 problems in 
intervention group and 60 in the control group) andthe need to increase doses (75 
problems in the intervention group and 21 in the control group). The pharmacist 
documented detection of 3 unnecessary drug therapies, 3 medications above 
recommended dose and 14 adverse drug reactions constituti g more than 10% of all 
MRPs. The usual care failed to document detection of any unnecessary drug therapy 
or very high doses and only managed to document detection of 3 adverse drug 
reactions. The classification and the count of the diff rent MRPs is summarised in 
table 4. 
Table 4: Medication related problems actioned 
Medication    Intervention  control  p-value 
     (n=45)   (n=42) 
 
Type of drug therapy problem  
 Unnecessary drug therapy   3 (1.67%)  0 (0%)    
 Additional drug therapy   71 (39.44%)  60 (66.67%)  
 Inappropriate drug   11 (6.11%)  5 (5.56%) 
 Dose too low    75 (41.67%)  21(23.33%)  
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Table 4 continued  
Medication    Intervention  control  P-value 
     (n=45)   (n=42) 
 
 Dose too high   3 (1.67%)  0 (0%)   
 Adverse drug reaction   14 (7.78%)  3 (3.33%)  
 Inappropriate compliance   3 (1.67%)  1 (1.11%)  
 Unclassified    0 (0%)   0 (0%) 
Total number of MRP    180   90  0.0058 
           (χ2-test) 
 
Mean MRP per patient   4.19   2.81  0.017 
           (z-test) 
 
MRP, medication related problem 
 
The treatment protocol used in the pharmacist-led DVCR clinic is based on the 
Scottish Intercollegiate Guidelines Network (SIGN) guidelines and developed in 
cooperation with doctors in the usual care indicates subclasses and generic names of 
antihypertensive medication and stating clearly the starting dose, maintenance dose 
and maximum dose for every medication in each of the 5 steps of the treatment stages. 
The 4-steps treatment protocol adapted by the usual care, is based on the SIGN 
guideline and the British National Formulary (BNF), states only the subclasses of 
antihypertensive therapy to be used without indicating a certain generic name or dose.  
 
Table 5: Guideline adherence  
   
 
Guideline     Intervention   control group  
 
Antihypertensive 
 Step 1     22   22    
Step 2     17   15 
 Step 3     13   4    
Step 4    10   1  
 Step 5     14   - 
Antiplatelet therapy adherence  37   11 
Lipid lowering therapy adherence  25   12 
 
 
The prescribing quality of statins and antiplatelet th rapy in the usual care and the 
pharmacist-led DCVR clinic varied. The reasons for guideline non-adherence in the 
pharmacist clinic were clearly documented; the type of drug and the dosage choice 
were the most eminent reasons for guideline non-adherence. The reasons for guideline 
non-adherence in the usual care were less well documented, leading to “unknown 
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reasons” being the major reason for guideline non-adherence.  Table 6 summarises the 
guideline non-adherence for platelet and Statin therapy. 
 
Table 6: Guideline non-adherence lipid lowering therapy and antiplatelet therapy    
 
Guideline     Intervention   control group  
 
Antiplatelet 
 Drug     4   0 
 Choice    1   3 
 Unknown   0   9 
 Non-applicable   3   5 
Total      8   17 
 
Lipid lowering therapy  
 Drug     5   3   
 Choice     13   8 
 Unknown   2   19 
 Non-applicable   0   1    
Total      20   32 
 
Four patients from the intervention group were admitted to the hospital after discharge 
from the clinic, the total number of admissions was 6. Only one patient from the 
control group was admitted to the hospital after th last appointment in the usual care, 
the total number of admissions for that patient was3. The reason for admission was 
unable to be obtained, but the speciality the patients were admitted to was able to be 
obtained. The length of hospitalisation was unable to be obtained. Table 7 summarises 
the admission data for the two populations.  
 
Table 7: Cardiology and vascular hospital admissions    
 
     Intervention   control group  
 
Number of patients admitted to the  4    1 
hospital  
 
time to first admission (months)  14     10 
 




6.3 Comparisons of outcome measures between renal diabetic 
patients and usual care.  
 
As stated in the method, the investigator was not granted access to the medical files of 
the patients experiencing care at the renal clinic. The subgroup of patients who 
attended the renal clinic was excluded from the study. The renal clinic was established 
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recently which does not fit the time parameter in the inclusion criteria for collecting 






Calculation of future study subjects size  
  
1) Calculation based on proportion of patients reaching target BP 
 










    n= number of subjects per group 
      x= proportion in group 1  








 = 36.69≈ 37 patients in each groups  
 










   n= number of subjects per group 
      x= proportion in group 1  












2) calculation based on SBP means 
 









    n= number required per group  
    SD = Standard Deviation  
    X= mean of group 1  









= 46.9 ≈ 47 patients in each group 
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   n= number required per group  
    SD = Standard Deviation  
    X= mean of group 1  








= 61.56 ≈ 62 patients in each group 
 
3) calculation based on DBP  
 









    n= number required per group  
    SD = Standard Deviation  
    X= mean of group 1  










 = 344.4≈  344 patients in each group 
 









    n= number required per group  
    SD = Standard Deviation  
    X= mean of group 1  

























A random patient was chosen from the pharmacist-led DCVR clinic and the usual 
care, the change in the SBP is plotted against the number of visits. The change in 
medical therapy is demonstrated under each appointment.  
 














7. Discussion  
 
7.1 Principal findings  
 
The study aimed to evaluate the feasibility of outcme measures and demonstrate 
differences, favouring the intervention offered by the pharmacist-led DCVR clinic 
over the usual care carried out by doctors in changes in physiological parameters, 
changes in pharmaceutical care plan and MRP for patients with diabetes attending 
hospital outpatient clinic at the WGH. 
 
7.1.1 Characterisation of diabetes population managed in NHS 
Lothian  
 
The intention was to recruit a control from those patients eligible to attend the 
pharmacist-led DCVR clinic. A lack of clearly defined parameters led to use kidney 
impairment measured in ACR and hypertension as risk factors to define the control 
group. These risk factors are used as referral criteria in the pharmacist-led DCVR 
clinic referral form.  
There was no statistical difference documented betwe n the intervention and the 
control group in baseline BP, ACR and cholesterol, h wever significant differences 
were detected in other characteristics. Patients in the intervention group were 
significantly older, had a longer duration of diabetes, a greater number of 
comorbidities, and a more significantly greater number of cardiovascular medications 
on referral. There might be a trend of more patients using insulin in the intervention 
group than patients in the control group. These diff rences indicate the significantly 
higher cardiovascular risk in the intervention group, influence the impact of the 
pharmacist-led DCVR clinic on cardiovascular risk reduction and complicate the 
process of feasibility evaluation of outcome measure . These variations question the 
validity of using the established referral criteria and how often they are being used. 
Other local work carried out by a student colleague from the University of Tromsø 
documented the detection of the referral of approximately 5% of eligible patients to 
the pharmacist–led DCVR clinic. It seems there were oth r factors that predicted 
referral than the ones established in the referral fo m.  
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It is proposed that subjects in the future study will be recruited prospectively and 
randomised into an intervention and a control group to eliminate variations and 
inconsistencies between the groups in terms of baseline characteristics and inclusion 
criteria will have to be clearly defined.  
 
7.1.2 Feasibility of outcome measures in the intervention and the 
control group  
 
Patients in the intervention group were referred to the pharmacist-led DCVR clinic 
with a greater number of cardiovascular medication and greater cardiovascular risk 
than the control group. However, they had a greater mean reduction of SBP and a 
greater proportion of patients reached the target BP set by the guidelines. These 
changes represented a statistical significance and coul  be considered as feasible 
outcome measures which can be used as primary end poi ts to calculate the future 
prospective population size.  The mean reduction in DBP was greater in the 
intervention group but was not statistically significant. Time elapsed to reach target 
BP between the two groups could not be compared due to the differences in the model 
of intervention delivery. The pharmacist-led DCVR clini  specialises in reducing 
cardiovascular risk, offers frequent follow up and patients are discharged after they 
reach treatment target. The usual care specialises in diabetes treatment but is not a 
specific cardiovascular clinic, can not offer frequnt follow up and only a small 
proportion of patients were discharged. The time elapsed to reach target BP could be 
recorded in the prospective study and used for analysis. 
 
The study did not detect significant difference in ACR reduction between the 
intervention and the control group. The ACR calculations were based on a proportion 
of the patients in both groups, as unreliable and incomplete data had to be excluded. It 
was anticipated that the ACR would be significantly reduced in the intervention group 
as the degree of kidney impairment is closely related to the hypertension status. 
However, the number of patients with nephropathy was greater in the intervention 
group. Patients in the control group were referred to the usual care to initiate or 
optimise diabetes treatment, the HbA1c reduction was significantly different between 
the control group and the intervention group as the p armacist-led DCVR clinic 
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specialises in cardiovascular risk only and does not recommend changes to the 
diabetes management. A trend was detected in reduction of ACR following the 
reduction of HbA1c in the control group and might attribute to the insignificant 
difference in ACR reduction between the control group and the intervention group. 
This finding is in concordance with a previous study conducted to evaluate the 
relationship between HbA1c and microvascular complications, which concluded there 
is a linear correlation between HbA1c and ACR and microvascular complications30.  
 The study concluded change in ACR is an unfeasible outcome measure due to 
insignificant reduction in ACR between the interventio  and the control group, 
however reduction in ACR could be used as a marker for reduced cardiovascular risk 
in the future study if both populations would have  comparable comorbidities profile 
(ACR, microalbuminurea and nephropathy). Also choosing groups with similar 
baseline HbA1c and duration of diabetes would eliminate the confounding effect the 
HbA1c has on ACR and microvascular disease. It is essential to record values 
accordingly to produce comparable data in both groups. 
 
The study documented a greater degree of reduction in total cholesterol in the control 
group, but did not represent a significant statistical difference. Total cholesterol 
calculations were based on a proportion of the population groups, incomplete and 
unreliable data had to be excluded. Most patients referred to the pharmacist-led 
DCVR clinic were prescribed statins prior to referral and were referred to the clinic to 
optimise treatment, while most patients referred to the usual care were not prescribed 
statins prior to referral and the lipid lowering treatment was initiated at the clinic. The 
difference in referral stage might explain the insig ificant difference in total 
cholesterol reduction. The lipid lowering therapy protocol is a simple two steps 
protocol that could be carried out without the need to titrate the doses frequently, 
which fits into the model of care delivery offered by the usual care.  
Changes in the treatment protocol of the usual care me about to include the 
recommendation of Statin therapy to all type 2 diabetics in the year 2005, which 
might explain the number of patients who were referd to the pharmacist-led DCVR 
clinic without being prescribed statin therapy. 
A trend was observed in the control group in terms of reduction in HbA1c followed 
by a reduction in total cholesterol. The reduction of HbA1c and the initiation of statin 
therapy to in the control group can explain the differences in reduction of total 
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cholesterol between the two groups. The correlation between reduced HbA1c and 
reduction in total cholesterol was in concordance with previous studies conducted to 
evaluate the effect of glycaemic control on lipid profiles31. 
The study concluded change in total cholesterol was unfeasible outcome measure; the 
change in cholesterol in the future study might not be an indicator on the impact of the 
clinic to reduce cardiovascular risk.  
Most medication changes were recorded in the letters o the GP, which is considered 
as a reliable source of changes in the pharmaceutical care plan. The changes 
recommended by the pharmacist led to a significant increase in the number of 
antihypertensive treatment and increased the dose of th  medications in the 
intervention group more than changes recommended by the doctors in the control 
group.  
These changes might explain the significant reduction in BP and the significant 
proportion of patients in the intervention group reaching target BP. There were some 
prominent differences in the antihypertensive treatment changes between the groups, 
the medications in the last steps of the treatment protocol for the pharmacist-led 
DCVR clinic (Spironolactone and α-blockers) were not prescribed by the doctors in 
the usual care, despite the collaboration between th  pharmacist and usual care 
doctors to develop the treatment protocol for the parmacist-led DCVR clinic.  
Changes in the number of antihypertensive medications between first and last 
appointment, differences in the doses increased and the numbers of medications 
increased to maximum dose could be a feasible outcome measure and could explain 
the changes in the physiological parameters.  
 
The study documented the detection of a significantly greater number of MRP and a 
significantly greater mean of problems for each patient in the intervention group than 
the control group. The detection of these problems led to optimising the 
pharmaceutical care plan and might have reduced the risk for CVD in the intervention 
group. The model of treatment delivery through the frequent follow up (every 6 to 8 
weeks) prompt by the achieved quality of prescribing a d the well-defined guidelines 
used by the pharmacist-led DCVR clinic attributed to the differences observed in the 
changes in the pharmaceutical plan and the number of MRPs. This can also be used to 
describe the significant change in SBP and the significa t number of patients reaching 
target BP. In contrast the infrequent follow up by the usual care and the vague 
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guidelines, which might have influenced the prescribing quality, explain the small 
change in BP, number of patients reaching BP target, pharmaceutical care plan and 
number of MRP actioned. 
 
The uneven distribution of related comorbidities between the two groups renders the 
differences in cardiology and vascular hospital admission insignificant. The 
intervention group had more patients admitted and a gre ter number of hospital 
admissions. Data concerning the length of hospitalisation and the outcome of 
hospitalisation were not provided by the Lothian health intelligence unit. The study 
found hospital admissions not feasible as an outcome measure, however in the future 
study hospital admissions can be valuable in evaluating the clinic when adequate 
numbers of subject with similar comorbidities and characteristics are included. 




7.2 strengths and limitations of the study 
 
7.2.1 Difficulties in retrieving data 
 
Using the diabetes database SCI-DC proved to be sub-optimal for data collection. 
SCI-DC database did not contain data on medication prescribed prior to first visit to 
the clinics and did not contain detailed documented physiological values. A more 
efficient way of collecting data was to access the patients’ medical record stored in 
the WGH medical record office. It was time consuming to grant authorisation to 
access the medical records, also the process of data retrieving from the medical 
records proved to be time consuming. During the process of data collection it was 
discovered medical records were destroyed for patients who did not receive treatment 
in the hospital for the past six years. The destruction of medical files reduced the 
number of patients in the intervention and led to only including patients who 
continued to receive treatment at the hospital after discharge from the pharmacist-led 
DCVR clinic. Medical records of deceased patients were removed from the medical 
record office and stored in a separate office, which proved to be inaccessible as 
authorisation was not granted to access these records. Mortality can be considered as a 
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primary end point, the number of deceased patients post discharge, time to mortality 
after discharge and the reason for mortality could be subjected to comparison between 
the different clinics. 
7.2.2 Identifying comparable populations 
 
The differences in the model of care delivery and the differences in the setup of the 
pharmacist-led DCVR clinic and the usual care clini led to unanticipated 
complications in selecting suitable patients for the study. The intervention group were 
selected from a list of patients discharged from the clinic before 2009 supplied by the 
clinic’s pharmacist.   
 The diabetes database SCI-DC could not be used to generate a list of patients 
discharged before 2009 from the usual care. Most patients attending the usual care do 
not get discharged despite being stable and reaching target physiological parameters, 
patients are still followed up, but less frequently (once a year). The usual care is a 
specific clinic for treating diabetes and not specific for treating hypertension and 
reducing CVD risk, however hypertension is managed in the clinic, but it’s not the 
main focus. The pharmacist-led DCVR clinic specialises in treating hypertension and 
reducing CVD risk.  
Identifying patients from the usual care was difficult and time consuming. SCI-DC 
database was used to identify patients with minimum SBP of 140 mmHg and DBP of 
80 mmHg and/or microalbuminurea (ACR >2.5 mg/mmol). However it could not be 
used to identify patients with similar comorbidities and duration of diabetes to the 
intervention group.  
It was planned to compare patients over a similar period of time, but proved to be sub-
optimal, intervention group patients were monitored every 6-8 weeks and most 
patients were discharged within a year of the firstappointment. The control group 
were followed up once or twice per annum. This led to change the inclusion criteria to 







7.2.3 Evaluation of guideline adherence 
 
The study design enabled data collection about guideline adherence, guideline non-
adherence and reasons for guideline non-adherence, how ver failed to develop an 
advanced guideline adherence assessment tool; the stage of treatment initiated for 
patients using cardiovascular medication prior to referral and the chronological order 
of adhering to guidelines was not recorded. Thus no conclusion about the assessment 




7.3 Comparisons to other studies  
 
7.3.1 Reduction in BP and Cholesterol 
  
Currently there are a limited number of studies published to evaluate the pharmacist-
led DCVR clinic. This makes it difficult to compare the study conducted to others 
published in the same field.  
 
In 2008 a study was conducted to evaluate the impact of the pharmacist-led DCVR 
clinic on cardiovascular risk which included 34 patien s, documented a significant 
reduction in BP 23/10mmHg (p<0.001), AMBP reduction of 13/9 mmHg in BP and 
an increase in the number of antihypertensives from2.82(±1.05) to 3.67(± 1.12). The 
study also documented a significant reduction in total cholesterol by 0.4mmol/L 
(p=0.002)21, however the study did not include a control group. The change in BP, 
total cholesterol and number of antihypertensive medication was compared between 
the first and last visit for the intervention group only. Hence no conclusion can be 
drawn on the significant difference of impact of the pharmacist clinic compared with 
usual care.  Our study documented 19/9 mmHg reduction in BP in the intervention 
group and 8/7 mmHg reduction in the control group. The reduction in total cholesterol 
was greater in the control group, 0.69 mmol/l for cntrol group and 0.14 mmol/l for 
intervention group, but did not represent a statistical difference (p=0.52). A great 
proportion of patients in the control group were not prescribed statins prior to referral 
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which might explain the great reduction in total cholesterol in the control group. The 
control group also had a suboptimal diabetes control, hence reduction in HbA1c led to 
reduction in total cholesterol.  
 
7.3.2 Impact on pharmaceutical care plan and hospital admissions  
 
The pharmacist intervention was evaluated and compared to the usual care in a study 
conducted on patients with left ventricular systolic dysfunction. The study included 
2614 patients with mild or moderate heart failure and evaluated the pharmacist’s 
impact on the pharmaceutical care. The primary outcome was death from any cause or 
admission for heart failure, secondary outcome was death from any cause or 
admission for cardiovascular cause. The study detected an improvement in the use of 
disease modifying medication; a greater number of initiations and dose increases in 
ACE-inhibitors, ARB and β-blockers were detected in the intervention group, 
however failed to demonstrate a positive impact of the pharmacist intervention on 
heart failure mortality and number of admissions; 337 patients died from the 
intervention and 331 from the control group (p=0.92)  The number of admissions for 
heart failure was 107 in the intervention group and114 for the control group (p=0.38) 
and the total number of admissions for any reason was 711 in the control group and 
695 in the control group (p=0.730)32. Our study has also demonstrated a significant 
difference in the number of cardiovascular medications initiated or increased 
(p<0.001) between the intervention and the control group, however there were more 
patients admitted from the intervention group and a greater number of total 
admissions. Patients in the intervention were significantly older, had longer duration 
of diabetes and had a greater number of comorbidities which explains the greater 










7.4 Future considerations 
 
7.4.1 Population size 
 
The size of the intervention and the control group to be included in the future study 
was calculated based on the primary outcome measures in duction of SBP, DBP and 
the number of patients in each group reaching BP targe . Reduction in ACR and total 
cholesterol and the difference in hospital admission rates were not appropriate in 
calculating the future study size because a greater impact was recorded in the control 
group.   
The change in SBP and the proportion of patients reaching BP target was statistically 
different between the intervention and the control g up. Reduction of DBP was 
greater in the intervention group but was not signif cant between the two groups. The 
future study population size was calculated based on DBP, depending on the power of 
the study, if the power of the study is chosen to be 80% and p<0.05 then each group 
in the study must contain at least 344 patients. If 90% power was chosen with p<0.05 
then at least 452 patients should be included. Recruiting this number of patients might 
be possible, but following up these patients will present a challenge for the 
pharmacist-led DCVR clinic. Collaboration between pharmacist-led DCVR clinics in 




7.4.2 Demographics of the study populations 
 
 In order to conduct a proper evaluation of the pharmacist intervention, control and 
intervention groups must be chosen with similar baseline characteristics in terms of 
physiological parameters, diabetes status and duration nd comorbidities. The main co 
founder that effected the evaluation of pharmacist intervention impact on BP, ACR 
and total cholesterol was HbA1c. Choosing groups with similar baseline HbA1c 
would eliminate the variation caused by differences in HbA1c. The distribution of 
comorbidities between the groups must be even, patients with previous comorbidities 
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are more likely to be admitted to hospital and have  longer duration of 
hospitalisation. It is also important to collect admission details which include specific 
specialities and diagnostic codes. All admission and even non cardiology or vascular 
admission should be collected and related admission should be included in the study.  
 
The study did not manage to demonstrate a great impact of the pharmacist-led DCVR 
clinic in the ACR due to the greater number of patients with nephropathy, longer 
duration of diabetes and the change detected in HbA1c in the control group which led 
to reduction in ACR.  
ACR is linearly correlated to BP, thus can reflect the effect of reduction of BP in the 
kidney function. There might be a need for subgroup analysis for patient with end 
stage renal failure (nephropathy). Patients can be divided into groups according to 
ACR; normal value (ACR 0-3.5 mg/mmol), microalbuminurea (ACR 3.5-35 
mg/mmol) and nephropathy (ACR>35mg/mmol) to ensure even distribution and 
avoid incorrect assessment. Fifty percent reduction in ACR for patients with 
nephropathy and number of patients reaching target of ACR <3.5 mg/mmol can be 
considered at as outcome for the future study.  
 
 
7.4.3 Economic evaluation  
 
Economic evaluation must be conducted to estimate the ffect of the pharmacist-led 
DCVRclinic on health expenditure. There are a limited number of papers published to 
estimate the cost effectiveness of the pharmacist led clinic. A study published in 2007 
estimated risk reduction with 11.9% for Coronary heart disease and 9.6% for 
cerebrovascular accident cost per event avoided was 34,708 pounds and 63,320 
pounds. However, the study contained a small number of subjects, lacked a control 
group and was conducted over a short period of time33.  
Cost benefit (gain and lose analysis in monetary) and cost effectiveness (cost in 
monetary and effect in gain in health e.g. year gained) can be conducted to evaluate 
the clinic. Direct and indirect costs must be taken into account. The cost to see a 
physician is much greater than the cost to see a pharmacist; however the model of 
care delivery offered by the pharmacist dictates frquent follow up and monitoring by 
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the pharmacist. Other direct costs must be taken into account such as the cost of 
materials used and cost of hospital space. Indirect cost must also be considered due to 
reduced efficiency and absence from workplace. 
The pharmacist intervention was shown to affect the p armaceutical care plan by 
initiating cardiovascular medications or increasing the dose more than the usual care, 
these changes come at a price, although might be leading to reduce cardiovascular 
risk; these changes are more expensive than the changes performed by the 

















8. Conclusion  
   
The study aimed to evaluate the feasibly of outcome measures between patients 
attending the pharmacist-led DCVR clinic and the usual care clinics led by 
physicians. The study documented significant differences in BP reduction, changes in 
pharmaceutical care plan and drug therapy problems actioned between the 
intervention and the control group.  
 
Feasibility study is a valuable tool to pave the way for a future randomised study by 
evaluating feasible outcome measures and uncovering unexpected difficulties prior to 
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Diabetes mellitus is chronic disease associated with severe morbidity and mortality. 
Diabetic patients are more likely to develop cardiovascular disease than non-diabetic 
patients1.It is estimated that 4% of the NHS Lothian population have diabetes mellitus 
and the majority of these patients have type 2 diabetes mellitus 2. The three main risk 
factors that increase the rate of development of cardiovascular disease are 
hyperglycaemia, dyslipidemia and hypertension. The p armacist-led diabetes 
cardiovascular risk reduction (DCVR) clinics were established to control these risk 
factors and to reduce the incidents of cardiovascular disease.  
 
The clinics co-operate with a multidisciplinary team to monitor patients, optimise 
treatments and prevent cardiovascular diseases, which makes the evaluation of the 
clinic’s impact difficult.  
Evaluations of the pharmacist led DCVR clinic have demonstrated a positive impact 
by optimising treatment, reducing blood pressure and improved lipid profiles 3 4.  
This feasibility study intends to inform a future prospective randomised trial by 
assessing the feasibility of data collection from patient records of those who have 
attended the existing pharmacist-led DCVR clinic. The feasibility of outcome 
measures will be assessed (prescribing quality, pharmaceutical care issues, hospital 
admissions and consultations, changes in blood pressu  and lipid measurements) to 

















2.1 To define outcome measures and the feasibility of data collection to inform a 
future randomised controlled prospective study to evaluate the pharmacist-led 
cardiovascular risk clinic.  
2.2 To define the size of effect of the pharmacist-led DCVR on outcome measures 
such as proportion of patients reaching blood pressur  target, proportion of quality 
standards reached for prescribing and hospital admission after discharge from the 
clinic to inform future power calculations.  





3.1  To characterise the diabetic population managed in NHS Lothian to 
include those who attend the secondary care diabetes clinics and those who attend 
or are eligible to attend to the pharmacist-led DCVR clinic 
3.2  To compare outcome measures between patients eligible to attend the 
pharmacist-led DCVR clinic whom attend the secondary c e diabetes clinic and 
patients who attend the pharmacist-led DCVR clinic i  terms of admission rates 
after discharge from clinic, reasons for admission, le gth of hospitalisation, 
proportion meeting target blood pressure, time to achieve target blood pressure, 
lipid targets and drug related problems to inform future evaluation.  To correlate 
with pharmaceutical care issues outcome measures between the two groups will 
be compared to explore the feasibility of future evaluation including economic 
evaluation. 
3.3  To compare time to dialysis, changes in albumin rea and blood 
pressure in the subgroup of patients who attend the renal diabetic clinic between 
those who are referred to the pharmacist and those who are managed by usual care 






4. Subjects and Settings 
 
The project is going to take place in the Western Ge eral Hospital, in the secondary 
care diabetes clinic and the pharmacist-led DCVR clinic.  
The secondary care diabetes clinic operates on a daily basis Monday to Friday and can 
see up to 30 patients per half-day session. The pati nts are seen by doctors to initiate 
or to optimise diabetes treatment. The doctors can recommend changes to the 
cardiovascular medication as well as diabetes medications, these recommendation are 
sent to the GP to commence the changes at primary care. Patients can be viewed 2-3 
times per year depending on their condition. If the patients are stable they will be 
offered only one review every year. A small number of patients are discharged every 
year to primary care.  
Approximately 100 patients are referred to the pharmacist-led DCVR clinic per 
annum. The clinic operates once a week and can review 6 patients per clinic. The 
patients are seen by pharmacist who specialises in cardiovascular medications. An 
agreement with lead clinician for the diabetes clini  that the pharmacist will review 
and make recommendations to treatment related to diabetic cardiovascular risk. The 
changes recommended are sent to the GP to commence in primary care. Patients can 
be seen frequently, the clinic can offer a review every 6 weeks. Patients are 
discharged from the clinic after two consecutive visits where blood pressure is on 
target. Whilst attending the pharmacist led DCVR clini  patients continue their 
treatment at the diabetes clinic and at the GP clinic. Only few patients are referred 
back to the pharmacist led DCVR clinic. Patients are seen once of twice a year in the 
usual care.  
The patients are going to be recruited retrospectivly using the electronic patient 




The patients will be recruited retrospectively using the electronic patient record 
Scottish Care Information – Diabetes Collaboration (SCI-DC) database.  
Patients managed by the clinic over a period of at least 12 months and discharged 
from the clinic for at least 3 years prior to the study commencing (discharged before 
January 2009).  
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Potential number of patients who might be eligible for future study will be estimated.  
 
Advice will be sought from the scientific officer for the South East Scotland Research 
Ethics Service as to whether or not application for research ethics approval is 
necessary.  If necessary an IRAS application will be made.  If not, a clinical 
governance project proposal form will be completed an submitted through the 
Pharmacy Quality Improvement team (QIT) for approval.   
 
Data will be anonymised in accordance with the data protection act.  No patient 






5.1.1 Patients suitable for inclusion will be identified retrospectively from the SCI-
DC database. A list of patients who have attended th  pharmacist clinic from 
2005 until 2009 will be generated from  SCI-DC, any inappropriate candidates 
that do not match the inclusion criteria are going to be excluded.  
 Using SCI-DC a search will be performed to identify patients who have 
attended the Diabetes clinic in the year of 2007 and identifying the patients 
that would have been eligible to attend the pharmacist-led DCVR clinic and 
patients that do not fit the inclusion criteria aregoing to be excluded.  
5.1.2 Data collection documents will be allocated an identification number linked to 
a list of patient names and date of birth to make it possible to collect additional 
patient information if required at a later period.  The list of patient names will 
be kept in a locked filing cabinet within the Education, Research and 
Development department within the pharmacy department at the WGH.  No 
patient identifiers are required for analysis.  Anonymised data will be 
transferred onto a password accessed Microsoft Access database.  
5.1.3 The general demographics of the population of patients who attend the 
secondary care clinic will be recorded and compared with those who attend or 
are eligible to attend the pharmacist’s clinic.  The demographics will include: 
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age, sex, type and duration of diabetes, co-morbidities, smoking habits, 
exercise habits and alcohol consumption. 
5.2.1 From the evidence base the investigator will develop outcome measures. 
5.2.2 Outcome measures will be agreed by the investigator and project supervisors. 
5.2.3 The feasibility of data collection of outcome measure  will be evaluated by 
accessing the SCI-DC database and using the pharmacist notes. 
5.2.4 Outcome measures will be compared between patients attending the secondary 
care diabetes clinic and those attending the pharmacist-led DCVR clinic. 
5.2.5 Outcome measures between the two groups will be compared and the 
feasibility of economic evaluation explored. 
5.3.1 Patients who attended the secondary care renal diabetic clinic will be 
identified using Apex program.  
5.3.2 Subgroup analysis between renal patients who attend the secondary care renal 
diabetes clinic and those attend the pharmacist-led DCVR clinic will be performed to 




6. Analysis and findings 
 
6.1 Descriptive statistical analysis will be used to describe the two groups 
including age, sex, smoking habits, alcohol consumption, duration of diabetes and co-
morbidities.  
6.2 The proportion of patients reaching blood pressure targets and other clinical 
parameters will be reported and compared between the two groups.  
6.3 The proportion of patients reaching quality standards for prescribing will be 
reported and compared between the two groups. 
6.4 The proportion of patients admitted to hospital following discharge from the 
clinic will be reported and compared between the two groups.  
6.5 Sub-group analysis of the renal diabetic patients in erms of time to dialysis, 
change in albuminurea and change in blood pressure will be compared with 
patients attending the pharmacist-led DCVR clinic. 
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Appendix 5 detailed physiological results  
 
 
Table 8 Physiological parameters 
 
Parameter     Intervention group   Control group  
 
 
Blood Pressure (mmHg) 
Number of patients     45    41 
Mean SPB first appointment  155.09    150.85 
           SD 19.02          SD 15.31  
Mean SPB last appointment  135.91    142.51 
           SD 10.39          SD 11.58 
 
Mean DPB first appointment   80.38    88.32 
           SD 10.31          SD 10.01 
Mean DPB last appointment   71.02    81.54 
            SD 7.79          SD 10.56 
 




Kidney functions  
 
 Mean Creatinine first appointment  116.70    72.61 
            SD 52.01          SD 11.64 
 Mean Creatinine last appointment  123.56    79.23 
            SD 56.05          SD 15.76 
 Mean change in Creatinine  6.85    6.61 
           SD 19.38          SD 11.35 
Number of patients    27    12  
  
Mean ACR first appointment  22.5    11.62 
            SD 47.80          SD 14.35 
 Mean ACR last appointment   19.61    6.15 
            SD 50.54                   SD 1.80 
 Mean change in ACR    2.89    5.47 
            SD 29.27          SD 14.13 
Number of patients    22    29 
     
 
Lipids  
Mean cholesterol first appointment  4.57    4.88 
     SD 0.95   SD 1.1 
Mean cholesterol last appointment  4.43    4.44 
     SD 0.86   SD 0.67 
 Mean change in cholesterol   0.14    0.69 
      SD 0.76   SD 1.21 




Mean HDL first appointment   1.22    1.14  
           SD 0.27          SD 0.31  
Mean HDL last appointment  1.15    1.83  
           SD 0.22           SD 0.34  
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Continued table 8 
 
Parameter     Intervention group   Control group  
 
Mean change in HDL    0.073    0.44  
           SD 0.11          SD 0.23 
 
Number of patients    6    35 
 
Mean Triglycerides first appointment 3.51    2.50  
           SD 1.98          SD 1.08 
Mean Triglycerides last appointment  3.19    1.92  
           SD 2.09            SD 1.08   
Mean change in Triglycerides   0.31    0.58  
           SD 0.65          SD 1.38 







































Appendix 6 guideline non-adherence  
 
The total number of antihypertensive guideline non-adherence in the intervention 
group was 86, deviation from the drug indicated by the guide line was the most 
prominent reason for none-adherence constituting 50% of the reasons for non-
adherence. The type of antihypertensives prescribed to the patients before being 
referred to the pharmacist-led clinic corresponded to the same subclass of 
antihypertensive indicated in the pharmacist treatmnt protocol, but were not the same 
generic names as in the protocol. The number of the different reason for non-guideline 
adherence are summarised in table 9.  
 
Table 9 Antihypertensive guideline non-adherence int rvention group 
 
Steps  Drug  Choice  Unknown Non-applicable    
 
 
Step 1  11  0  2  2    
Step 2   7  4  3  4 
Step 3   8  3  4  6 
Step 4   16  0  0  5 





Table 10 Antihypertensive guideline non-adherence control group 
 
Steps  Drug  Choice  Unknown Non-applicable    
 
 
Step 1   0  0  4   0  
Step 2  0  0  7   1  
Step 3  0  0  8   0  
Step 4  0  0  5   0 
 
 
 
